Dataset Information

Estimation of Nuwiq^® (simoctocog alfa) activity using one-stage and chromogenic assays-Results from an international comparative field study.

ABSTRACT:

Background

Accurate determination of coagulation factor VIII activity (FVIII:C) is essential for effective and safe FVIII replacement therapy.

Fviii

C can be measured by one-stage and chromogenic substrate assays (OSAs and CSAs, respectively); however, there is significant interlaboratory and interassay variability.

Aims

This international comparative field study characterized the behaviour of OSAs and CSAs used in routine laboratory practice to measure the activity of Nuwiq^® (human-cl rhFVIII, simoctocog alfa), a fourth-generation recombinant human FVIII produced in a human cell line.

Methods

FVIII-deficient plasma was spiked with Nuwiq^® or Advate^® at 1, 5, 30 and 100 international units (IU)/dL. Participating laboratories analysed the samples using their routine procedures and equipment. Accuracy, inter- and intralaboratory variation, CSA:OSA ratio and the impact of different OSA and CSA reagents were assessed.

Results

Forty-nine laboratories from 9 countries provided results. Mean absolute FVIII:C was comparable for both products at all concentrations with both OSA and CSA, with interproduct ratios (Nuwiq^® :Advate^® ) of 1.02-1.13. Mean recoveries ranged from 97% to 191% for Nuwiq^® , and from 93% to 172% for Advate^® , with higher recoveries at lower concentrations. Subgroup analyses by OSA and CSA reagents showed minor variations depending on reagents, but no marked differences between the two products. CSA:OSA ratios based on overall means ranged from 0.99 to 1.17 for Nuwiq^® and from 1.01 to 1.17 for Advate^® .

Conclusions

Both OSAs and CSAs are suitable for the measurement of FVIII:C of Nuwiq^® in routine laboratory practice, without the need for a product-specific reference standard.

SUBMITTER: Tiefenbacher S

PROVIDER: S-EPMC6851970 | biostudies-literature |

REPOSITORIES: biostudies-literature

ACCESS DATA

Similar Datasets

Project description:BackgroundMonocytes are myeloid cells that reside in the blood and bone marrow and respond to inflammation. At the site of inflammation, monocytes express cytokines and chemokines. Monocytes have been shown to be cytotoxic to tumor cells in the presence of pro-inflammatory cytokines such as Interferon Alpha, Interferon Gamma, and IL-6. We have previously shown that monocytes stimulated with both interferons (IFNs) results in synergistic killing of ovarian cancer cells. We translated these observations to an ongoing clinical trial using adoptive cell transfer of autologous monocytes stimulated ex vivo with IFNs and infused into the peritoneal cavity of patients with advanced, chemotherapy resistant, ovarian cancer. Here we describe the optimization of the monocyte elutriation protocol and a cryopreservation protocol of the monocytes isolated from peripheral blood.MethodsCounter flow elutriation was performed on healthy donors or women with ovarian cancer. The monocyte-containing, RO-fraction was assessed for total monocyte number, purity, viability, and cytotoxicity with and without a cryopreservation step. All five fractions obtained from the elutriation procedure were also assessed by flow cytometry to measure the percent of immune cell subsets in each fraction.ResultsBoth iterative monocyte isolation using counter flow elutriation or cryopreservation following counter flow elutriation can yield over 2 billion monocytes for each donor with high purity. We also show that the monocytes are stable, viable, and retain cytotoxic functions when cultured with IFNs.ConclusionLarge scale isolation of monocytes from both healthy donors and patients with advanced, chemotherapy resistant ovarian cancer, can be achieved with high total number of monocytes. These monocytes can be cryopreserved and maintain viability and cytotoxic function. All of the elutriated cell fractions contain ample immune cells which could be used for other cell therapy-based applications.

Project description:In order to evaluate the impact of water deficit in field conditions, researchers or breeders must set up large experiment networks in very restrictive field environments. Experience shows that half of the field trials are not relevant because of climatic conditions that do not allow the stress scenario to be tested. The PhénoField® platform is the first field based infrastructure in the European Union to ensure protection against rainfall for a large number of plots, coupled with the non-invasive acquisition of crops' phenotype. In this paper, we will highlight the PhénoField® production capability using data from 2017-wheat trial. The innovative approach of the PhénoField® platform consists in the use of automatic irrigating rainout shelters coupled with high throughput field phenotyping to complete conventional phenotyping and micrometeorological densified measurements. Firstly, to test various abiotic stresses, automatic mobile rainout shelters allow fine management of fertilization or irrigation by driving daily the intensity and period of the application of the desired limiting factor on the evaluated crop. This management is based on micro-meteorological measurements coupled with a simulation of a carbon, water and nitrogen crop budget. Furthermore, as high-throughput plant-phenotyping under controlled conditions is well advanced, comparable evaluation in field conditions is enabled through phenotyping gantries equipped with various optical sensors. This approach, giving access to either similar or innovative variables compared manual measurements, is moreover distinguished by its capacity for dynamic analysis. Thus, the interactions between genotypes and the environment can be deciphered and better detailed since this gives access not only to the environmental data but also to plant responses to limiting hydric and nitrogen conditions. Further data analyses provide access to the curve parameters of various indicator kinetics, all the more integrative and relevant of plant behavior under stressful conditions. All these specificities of the PhénoField® platform open the way to the improvement of various categories of crop models, the fine characterization of variety behavior throughout the growth cycle and the evaluation of particular sensors better suited to a specific research question.

Project description:ObjectiveTo introduce a novel technology currently under final development before regulatory approvals for the furtherment of cataract surgery, using the FemtoMatrix® laser system, and to demonstrate its safety and efficacy as compared to standard ultrasound phacoemulsification.MethodsThirty-three patients with bilateral cataracts were operated on with one eye undergoing PhotoEmulsification® treatment on the FemtoMatrix® device and the contralateral eye receiving the control procedure, i.e., standard ultrasound phacoemulsification treatment. The number of "zero-phaco" procedures (denoting that I/A alone was sufficient to aspirate the lens fragments and that no ultrasound energy was needed) was recorded and Effective Phaco Time (EPT) values were compared. The patient follow-up was 3 months.ResultsThirty-three eyes from a population with a mean cataract grade of 2.6 were treated on the FemtoMatrix®, of which 29 were "zero-phaco" (88%). All patients were operated on by a single surgeon who was a relative novice to the technology (63 patients treated prior to this study). Conversely, of the 33 fellow eyes who underwent standard ultrasound phacoemulsification, none were zero-phaco (0%) - all required varying degrees of ultrasound energy to make lens aspiration possible. The mean EPT was significantly lower in the PhotoEmulsification® laser group (0.2 ± 0.8 s) than in the phaco group (1.3 ± 1.2 s) (p < 0.0001). The safety profiles of the two procedures were comparable, with no device-related adverse events noted.ConclusionFemtoMatrix® is a promising femtosecond laser platform that, when compared to phacoemulsification, significantly decreases or eliminates EPT altogether. The system is used to perform PhotoEmulsification®, making zero-phaco cataract procedures feasible including in high-grade cataracts (>3). It enables personalized treatment by automatically measuring and adapting the laser energy required to obtain the most efficient cutting of the crystalline lens. This new technology appears to be safe and effective in cataract surgery.

Project description:IntroductionDeveloping countries can improve their pharmacovigilance systems by analysing their own medication safety data.ObjectiveThe aims of this study were to characterize Uganda's reported adverse drug reaction (ADR) onsets in 2012-2015 that were registered on VigiBase® by 31 December 2017, to document delays in international visibility and the influence of covariates on this delay from ADR onsets in 2013 + 2014, to examine data quality, and to illustrate analytical approaches for safety data, particularly for patients receiving antiretroviral therapy (ART).MethodsInternational delay was defined as elapsed time from complete ADR onset date to entry date on VigiBase®, with covariates examined using Cox proportional hazards regression. Simple random sampling was used to locate the paper-based ADR forms for data quality assurance. Disproportionality for signal detection focused on serious singleton ADR onsets in patients receiving ART.ResultsUganda's VigiBase® had 1018 patient entries with complete ADR onset dates: 260 in 2012, 293 in 2013, 305 in 2014 and 160 in 2015. Only 16% (154/953) of ADR onsets in 2012-2015 were in patients aged < 20 years for whom randomly sampled ADR forms were less fully completed; 87% (889/1018) comprised a singleton sign/symptom; half were serious. Median delay from ADR onset to international visibility was 11 months for ADR onsets in 2013 + 2014, and longest for healthcare professionals other than pharmacists and physicians. Disproportionality for serious ADR onsets in patients receiving ART included anaemia with zidovudine, renal impairment with tenofovir, Stevens-Johnson syndrome with nevirapine and skin rash with efavirenz.ConclusionsBarely one ADR onset per day was registered on VigiBase® from those submitted to Uganda's National Pharmacovigilance Centre during 2012-2014; only one in six was from patients aged < 20 years. Paediatric pharmacovigilance requires more emphasis in Uganda. Delays from reported ADR onset to international visibility on VigiBase® need to reduce dramatically. Quality assurance revealed rectifiable data entry deficits. Signal detection performed well for patients receiving ART.

Dataset Information

Estimation of Nuwiq^® (simoctocog alfa) activity using one-stage and chromogenic assays-Results from an international comparative field study.

Background

Fviii

Aims

Methods

Results

Conclusions

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets

Dataset Information

Estimation of Nuwiq® (simoctocog alfa) activity using one-stage and chromogenic assays-Results from an international comparative field study.

Background

Fviii

Aims

Methods

Results

Conclusions

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets

Estimation of Nuwiq^® (simoctocog alfa) activity using one-stage and chromogenic assays-Results from an international comparative field study.